Cover Image
市場調查報告書

白細胞介素-1&s;:開發中產品分析

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 368725
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素-1&s;:開發中產品分析 Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 85 Pages
簡介

本報告提供以白細胞介素-1&s;為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素-1&s; 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • AbbVie Inc
  • Affibody AB
  • Anacor Pharmaceuticals, Inc.
  • Apexigen, Inc.
  • Cell Medica Limited
  • Handok Inc.
  • Immune Response BioPharma, Inc.
  • Novartis AG
  • Omnitura Therapeutics Inc.
  • Opsona Therapeutics Limited
  • Peptinov SAS
  • R-Pharm
  • Regeneron Pharmaceuticals Inc
  • TWi Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0442TDB

Summary

Global Markets Direct's, 'Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
  • The report reviews Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview
  • Therapeutics Development
    • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Stage of Development
    • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Therapy Area
    • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Indication
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Companies
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Universities/Institutes
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Affibody AB
    • Anacor Pharmaceuticals, Inc.
    • Apexigen, Inc.
    • Cell Medica Limited
    • Handok Inc.
    • Immune Response BioPharma, Inc.
    • Novartis AG
    • Omnitura Therapeutics Inc.
    • Opsona Therapeutics Limited
    • Peptinov SAS
    • R-Pharm
    • Regeneron Pharmaceuticals Inc
    • TWi Pharmaceuticals, Inc.
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Drug Profiles
    • ABT-981 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-4161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diacerein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2681 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-2351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMN-54 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PPV-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rilonacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPH-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule Inflammasome Modulator Programme - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Dormant Projects
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Discontinued Products
  • Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Featured News & Press Releases
    • Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment
    • Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab
    • Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
    • Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir
    • Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet
    • Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients
    • Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting
    • Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes
    • Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia
    • Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan
    • Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China
    • Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan
    • Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States
    • Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States
    • Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AbbVie Inc, H2 2016
  • Pipeline by Affibody AB, H2 2016
  • Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
  • Pipeline by Apexigen, Inc., H2 2016
  • Pipeline by Cell Medica Limited, H2 2016
  • Pipeline by Handok Inc., H2 2016
  • Pipeline by Immune Response BioPharma, Inc., H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Omnitura Therapeutics Inc., H2 2016
  • Pipeline by Opsona Therapeutics Limited, H2 2016
  • Pipeline by Peptinov SAS, H2 2016
  • Pipeline by R-Pharm, H2 2016
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Pipeline by TWi Pharmaceuticals, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Dormant Projects (Contd..4), H2 2016
  • Discontinued Products, H2 2016
  • Discontinued Products (Contd..1), H2 2016
  • Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top